Adamas Pharmaceuticals, Inc.

Adamas Pharmaceuticals, Inc. company information, Employees & Contact Information

Updated June 2026

Quick answer

Adamas Pharmaceuticals, Inc. is a Pharmaceutical Manufacturing company and founded in 2002. It has approximately 43 employees on record. Contact data was last refreshed in June 2026. Find Adamas Pharmaceuticals, Inc.'s verified employee emails, phone numbers, headquarters address, and key decision makers below.

At Adamas, our mission and vision are clear: deliver innovative medicines that reduce the burden of neurological diseases on patients, caregivers, and society. We are a fully-integrated company focused on growing a portfolio of therapies to address a range of neurological diseases.

Company Details

Employees
43
Founded
2002
Address
Emeryville, California, Us
Phone
5104280519
Email
in****@****rma.com
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Emeryville, California
Looking for a particular Adamas Pharmaceuticals, Inc. employee's phone or email?

Adamas Pharmaceuticals, Inc. Questions

News

Adamas Announces New Employment Inducement Grant - citybiz

Adamas Announces New Employment Inducement Grant citybiz

as an Adjunctive Treatment to levodopa/carbidopa in Parkinson’s Disease Patients Experiencing OFF Episodes - Business Wire

as an Adjunctive Treatment to levodopa/carbidopa in Parkinson’s Disease Patients Experiencing OFF Episodes Business Wire

Actavis and Adamas Announce FDA Approval of Namzaric™, a Fixed-Dose Combination of Memantine Extended-Release and Donepezil Hydrochloride - PR Newswire

Actavis and Adamas Announce FDA Approval of Namzaric™, a Fixed-Dose Combination of Memantine Extended-Release and Donepezil Hydrochloride PR Newswire

Adamas Announces FDA Approval of GOCOVRI™ as First and Only - GlobeNewswire

Adamas Announces FDA Approval of GOCOVRI™ as First and Only GlobeNewswire

Actavis Launches NAMZARIC™ (memantine hydrochloride extended-release and donepezil hydrochloride), a Fixed-Dose Combination Therapy for the Treatment of Moderate to Severe Alzheimer's Disease - PR Newswire

Actavis Launches NAMZARIC™ (memantine hydrochloride extended-release and donepezil hydrochloride), a Fixed-Dose Combination Therapy for the Treatment of Moderate to Severe Alzheimer's Disease PR Newswire

Top Adamas Pharmaceuticals, Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant